- Home
- Free App Analytics
- Side Onco Skin
- Side Onco Skin Vs. OncoClic
Side Onco Skin vs OncoClic Usage & Stats
Side Onco Skin is a free mobile app developed by Avène Dermatological Laboratories in partnership with oncodermatology specialist Dr. Vincent Sibaud (Institut Universitaire du Cancer, Toulouse).
Side Onco Skin is intended exclusively for healthcare professionals who want to train in the dermatological complications of cancer treatments.
The Side Onco Skin app has been designed to support and train healthcare professionals in treating and advising patients suffering from dermatological symptoms related to chemotherapy, targeted therapy, immunotherapy or radiotherapy.
"With the Side Onco Skin app, you can:
- Learn to recognize the key symptoms and identify the inducing molecules;
- Improve the care of your patients and their quality of life;
- Test your knowledge with numerous quizzes and practical cases;
- Be regularly informed about the developments of new treatments and their side effects."
The Side Onco Skin app does not replace scientific training, but complements it by enabling you to broaden your knowledge in a practical and interactive way.
- Apple App Store
- Free
- Medical
Store Rank
- -
OncoClic est la première application en Oncologie à destinations des professionnels de santé.
Notre objectif : informer, assister et accompagner !
Informer via un média d’alerte sur l’actualité en Oncologie.
Assister les professionnels de santé via des outils indispensables au quotidien.
Accompagner les praticiens dans la recherche d’essais cliniques.
Cette application ne remplace pas la consultation d’un professionnel de santé.
- Apple App Store
- Free
- Medical
Store Rank
- -
Side Onco Skin vs. OncoClic ranking comparison
Compare Side Onco Skin ranking trend in the past 28 days vs. OncoClic
Rank
No Data Available
Side Onco Skin vs. OncoClic ranking by country comparison
Compare Side Onco Skin ranking trend in the past 28 days vs. OncoClic
No Data to Display
Compare to any site with our free trial
January 18, 2026